Suchergebnisse - "MERIC-BERNSTAM FUNDA"

PubPharm (1.024)

1

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer : Results From the Phase I TROPION-PanTumor01 Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Bardia, A. | Krop, I. | Kogawa, T. | +17

2

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity : The NCI PDXNet Consensus Recommendations

enthalten in: Molecular cancer therapeutics | 2024

von Meric-Bernstam, F. | Lloyd, M. | Koc, S. | +31

3

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor : Pooled Safety Analysis of 469 Patients

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Meric-Bernstam, F. | Hollebecque, A. | Furuse, J. | +7

4

Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan

enthalten in: Cancer treatment reviews | 2024

von Heist, R. | Sands, J. | Bardia, A. | +12

5

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

enthalten in: The oncologist | 2024

von Piha-Paul, S. | Xu, B. | Dumbrava, E. | +22

6

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers : the RE-RAFFLE study

enthalten in: Molecular cancer | 2024

von Nelson, B. | Roszik, J. | Ahmed, J. | +11

7

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

enthalten in: Molecular cancer | 2024

von Nelson, B. | Roszik, J. | Ahmed, J. | +11

8

Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer

enthalten in: Annals of surgical oncology | 2024

von Higgins, T. | Kantor, O. | Harrison, B. | +11

9

TROP-2-양성 암을 표적화하기 위한 키메라 항원 수용체

enthalten in: Europäisches Patentamt | 2024

von REZVANI KATY | ACHARYA SUNIL | MERIC BERNSTAM FUNDA | +3

10

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

enthalten in: NPJ precision oncology | 2024

von Subbiah, V. | Gouda, M. | Iorgulescu, J. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[103]